Biotech and Pharmaceuticals Life Sciences

  • Aug 1- Pfizer Inc said it had acquired privately held gene therapy developer Bamboo Therapeutics Inc in a deal worth up to $645 million to boost its presence in the treatment of rare diseases. The U.S. Food and Drug Administration has yet to approve any gene therapies but Europe has approved two- a treatment from GlaxoSmithKline for a rare immune disorder in...

  • LONDON, July 28- AstraZeneca's chief executive believes a rival could spot the growing value of its drug pipeline but declined to say on Thursday if the group was likely to be a takeover target once more, two years after seeing off a bid from Pfizer. Citi analyst Andrew Baum suggested in a note this week that AstraZeneca's biotech expertise and advanced...

  • LONDON, July 27- GlaxoSmithKline has bought global rights to an experimental drug from Johnson& Johnson for up to 175 million pounds, raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker recently launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more...

  • Medical students and members of the public will be able to watch a live hernia surgery in 360-degree virtual reality (VR) later this week.

  • An MRI scan of an Alzheimer patient's brain.

    Research shown at the Alzheimer's Association International Conference suggests people with complex careers may be resistant to the disease.

  • Venter on killing cancer

    J. Craig Venter, Human Longevity Inc., CEO, on how science is on the verge of finding cancer in its earliest stages.

  • CNBC Pro: Big business of human longevity

    J. Craig Venter, Human Longevity Inc., CEO, discusses how advances in technology could expand human life spans.

  • July 19- Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion. The deal for the tiny Cambridge, Massachusetts- based company comes just at little...

  • NEW YORK, July 14- Martin Shkreli, the former pharmaceutical executive who last year became a lightning rod for criticism of soaring prescription drug prices, is now scheduled to go on trial in June 2017 in the U.S. government's securities fraud case against him. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against...

  • NEW YORK, July 14- Martin Shkreli, the former pharmaceutical executive who became a lightning rod for criticism of soaring prescription drug prices last year, is now scheduled to go on trial in June 2017 in the U.S. government securities fraud case. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan...

  • NEW YORK, July 14- A federal judge on Thursday scheduled a trial for June 2017 in the U.S. government's securities fraud case against former pharmaceutical executive Martin Shkreli, who became a lightning rod last year for criticism of soaring prescription drug prices. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case...

  • District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan Greebel, a former lawyer for Retrophin Inc, a biopharmaceutical company which Shkreli headed until 2014..

  • July 12- Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.. Prevnar has been buoying Pfizer's revenue, helping the company beat Wall Street estimates. The Prevnar range of products grossed annual sales of $6.25 billion in 2015, up 40 percent from a year...

  • Elizabeth Holmes

    U.S. regulators have banned Elizabeth Holmes, the chief executive of Theranos, from owning or operating a laboratory for at least two years.

  • *Accord with Walter Reed Army Institute of Research. PARIS/ LONDON, July 6- French drugmaker Sanofi said on Wednesday it had struck a research and development deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus. The tie-up with the Walter Reed Army Institute of Research in the United States gives Sanofi access to a...

  • LONDON, June 22- Roche is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker's older cancer medicines start to grab business next year, its chief executive said on Wednesday. Big wins for three new drugs in recent months have helped to offset what Roche's Severin Schwan acknowledges as a serious...

  • June 20- Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine. In February, the World Health Organization declared Zika a global public health emergency. India's Bharat Biotech is another company that is in the...

  • June 20- Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval to start an early stage human trial testing their Zika vaccine. The early-stage study will enroll 40 healthy subjects and evaluate safety, tolerability and immune response generated by the vaccine GLS-5700. "We plan to dose our first...

  • Modern medicine's latest tool? Gene editing

    CNBC's Meg Tirrell talks with Dr. Jennifer Doudna, UC Berkeley professor and CRISPR technology pioneer about the scientific breakthrough of editing genes as a possible cure for hundreds of diseases.

  • The repercussions of the Bayer-Monsanto deal

    Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.